

# New Venturetec

## NET ASSET VALUE - January 31, 2018

Shares issued private	4'500'000	Price: USD 23.83	USD 107'250'000
Shares issued IPO	500'000	Price: CHF 33.00 (ex.rate 1.47)	USD 11'250'000
	<b>5,000,000</b>		<b>USD 118'500'000</b>

<b>Total paid in capital</b>	<b>USD</b>	<b>118'500'000.00</b>
------------------------------	------------	-----------------------

Realized gain* (since inception to date)	USD	75'124'350.98
Realized loss* (since inception to date)	USD	109'585'211.82

\*inclusive reinvestments

### Investment appreciation of current portfolio companies

Unrealized gain	USD	6'715'944.43
Unrealized loss	USD	0.00
<b>Total appreciation</b>	<b>USD</b>	<b>6'715'944.43</b>

### NAV

Cost of investments	USD	28'769'158.69
Appreciation of investments	USD	6'715'944.43
Estimated value of investments	USD	<b>35'485'103.12</b>
Convertible Notes	USD	-14'086'201.66
Loan	USD	-8'163'225.78
Bank Loan	USD	0.00
Accrued expenses	USD	0.00
Accounts receivables	USD	0.00
Cash at bank	USD	1'044'242.96
<b>Estimated value</b>	<b>USD</b>	<b>14'279'918.64</b>
<b>NAV per share USD</b>		<b>2.86</b>
<b>NAV per share CHF</b>		<b>2.66</b>

Exchange rate USD/CHF	0.9326
<b>Closing Market Price January 31, 2018</b>	<b>CHF 2.70</b>

**New Venturetec**  
**NAV - January 31, 2018**

INDUSTRY/ COMPANY	AMOUNT USD	% CAPITAL	SECURITIES	PRICE COST	PRICE REPORTED	UNREALIZED GAIN (LOSS)	TOTAL EST. VALUE	% NAV
1. Osiris Therapeutics, Inc.	23'780'932.93	82.7	4'103'301 Common Shares	5.80	7.12	5'434'570.19	29'215'503.12	79.9
2. Myriad Genetics	4'988'225.76	17.3	170'000 Shares	29.34	36.88	1'281'374.24	6'269'600.00	17.2
<b>TOTAL</b>	<b>28'769'158.69</b>	<b>100.0</b>				<b>6'715'944.43</b>	<b>35'485'103.12</b>	<b>97.1</b>